Skip to main content
. 2019 Nov 25;173(2):402–415. doi: 10.1093/toxsci/kfz235

Figure 3.

Figure 3.

Original optical action potential recordings showing each hiPSC-CM cell type electrophysiological responses to a subset of compounds from each risk category of CiPA compounds. A, hiPSC-CM cell-type specific responses to the low-risk compound nitrendipine (18A09, calcium channel blocker). Nitrendipine shortened the APD in the CDI and MCH hiPSC-CMs, whereas the CLS cells were completely quiescent at the 2 highest doses (100% of CLS functional mature syncytia were quiescent at each concentration). B, The hiPSC-CM cell-type specific responses to the intermediate-risk compound domperidone (18A06, antiemetic). Drug-induced reentry (rotors) was observed in the CLS and MCH hiPSC-CMs at high concentration, CDI hiPSC-CMs responded with early after depolarizations at the highest concentration. C, hiPSC-CM cell-type specific responses to the high-risk compound vandetanib (18A19, anticancer kinase inhibitor). All cell types showed APD prolongation and the MCH and CLS cells responded to high concentration with EADs. D, The hiPSC-CM cell-type specific response to the high-risk compound sotalol (18A22, β blocker). All cell types responded with APD prolongation.